Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status

International Journal of Cancer

Volumn 121, Issue 5, 2007, Pages 1017-1020

  Moller, Pal ^a   Evans, D Gareth ^b   Reis, Marta M ^c   Gregory, Helen ^d   Anderson, Elaine ^e   Maehle, Lovise ^a   Lalloo, Fiona ^b   Howell, Anthony ^f   Apold, Jaran ^g   Clark, Neal ^a   Lucassen, Anneke ^h   Steel, C Michael ⁱ  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d NHS GRAMPIAN   (United Kingdom)

^e South East of Scotland Breast Screening Programme ^*  (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ Breast Screening Centre   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Early diagnosis; Inherited; Outcome; Prospective trail

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARCINOMA IN SITU; EARLY DIAGNOSIS; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NORWAY; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; UNITED KINGDOM;

ADULT; BREAST NEOPLASMS; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HUMANS; MIDDLE AGED; MUTATION; POPULATION SURVEILLANCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547110127     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22789     Document Type: Article

References (30)

1. Steel CM. Cancer of the breast and female reproductive tract. Ch. 93. In: Emery and Rimoin's principles and practice of medical genetics, 5th edn: DL Rimoin, JM Connor, RE Pyeritz, BR Korf, Eds. New York: Churchill Livingston, 2007. pp 2093-2121.
2. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
3. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
4. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM et al. The pathology of familial breast cancer: histological features of cancers in families not due to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
5. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Danmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
6. Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, van den Ouweland A, Obdeijn IM, Klijn JG. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001;19:924-30.
7. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Bruggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006;17:391-400.
8. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.
9. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics. BRCA mutations and oophorectomy. Int J Cancer 2002;101:555-9.
10. Moller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, Steel CM, Apold J, Lalloo F, Maehle L, Preece P, Gregory H et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. Dis Markers 1999:15;179-86.
11. Moller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers ion a Norwegian prospective series. Eur J Cancer 2001;37:1027-32.
12. Scottish/Northern Irish BRCA1/BRCA2 Consortium. BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J Cancer 2002;88:1256-62.
13. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: Predictive value of immunhistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;2310-18.
14. Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Bremond A, Treilleux I, Martin A, Romestaing P, Raudrant D, Rudigoz RC et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res 2007;101:233-45.
15. Evans DG, Howell A. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res 2004; 6:E7
16. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2005;5:135-42
17. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Begin LR. Primary node-negative breast cancer in BRCA1 mutation-carriers has a poor outcome. Ann Oncol 2000;11:307-13.
18. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71.
19. Schrag D, Kuntz KM, Garber J, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000;283:617-24.
20. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998;18:365-75.
21. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-postive patients. J Clin Oncol 1998;16: 979-85.
22. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am 2000;6:13-20.
23. van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA. Decision analysis of prophylactic surgery or screening for BRCA1 mutation-carriers: a more prominent role for oophorectomy. J Clin Oncol 2002;20:2092-100.
24. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
25. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
26. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation-carriers with breast magnetic resonance imaging. JAMA 2006;295: 2374-84.
27. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M et al. Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-31.
28. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study. Lancet 2005;365:1769-78.
29. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S et al. Efficacy of MRI and mammography for breast cancer screening in women with a family history or genetic predisposition. N Engl J Med 2004;351:427-37.
30. Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabo A, Apold J, Skaane P, Moller P. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007;Feb 20 [Epub ahead of print].